New malaria vaccine shows promise in early safety trial
NCT ID NCT02014727
First seen Jan 07, 2026 · Last updated May 24, 2026 · Updated 23 times
Summary
This study tested a new malaria vaccine in 66 healthy adults from Europe and Africa. The goal was to see if the vaccine is safe and how the immune system responds. Participants received three doses of the vaccine over six months, and researchers monitored for side effects and immune reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA,FALCIPARUM are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CIC BT 505 de vaccinologie Cochin Pasteur. Hôpital Cochin Bâtiment Lavoisier 27 rue du faubourg St Jacques.
Paris, 75014, France
-
CNRFP
Ouagadougou, Ouagadougou, Burkina Faso
Conditions
Explore the condition pages connected to this study.